- Home
- NTLA vs MAX Comparison
NTLA vs MAX Comparison
Compare NTLA & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- MAX
- Stock Information
- Founded
- NTLA 2014
- MAX 2014
- Country
- NTLA United States
- MAX United States
- Employees
- NTLA N/A
- MAX N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MAX Industrial Machinery/Components
- Sector
- NTLA Health Care
- MAX Industrials
- Exchange
- NTLA Nasdaq
- MAX Nasdaq
- Market Cap
- NTLA 710.1M
- MAX 582.4M
- IPO Year
- NTLA 2016
- MAX 2020
- Fundamental
- Price
- NTLA $6.87
- MAX $10.19
- Analyst Decision
- NTLA Buy
- MAX Buy
- Analyst Count
- NTLA 20
- MAX 7
- Target Price
- NTLA $38.40
- MAX $17.21
- AVG Volume (30 Days)
- NTLA 5.0M
- MAX 463.2K
- Earning Date
- NTLA 05-08-2025
- MAX 04-30-2025
- Dividend Yield
- NTLA N/A
- MAX N/A
- EPS Growth
- NTLA N/A
- MAX N/A
- EPS
- NTLA N/A
- MAX 0.28
- Revenue
- NTLA $45,569,000.00
- MAX $1,002,364,000.00
- Revenue This Year
- NTLA N/A
- MAX $23.97
- Revenue Next Year
- NTLA N/A
- MAX $9.79
- P/E Ratio
- NTLA N/A
- MAX $36.80
- Revenue Growth
- NTLA N/A
- MAX 148.62
- 52 Week Low
- NTLA $5.90
- MAX $7.33
- 52 Week High
- NTLA $28.18
- MAX $20.91
- Technical
- Relative Strength Index (RSI)
- NTLA 38.33
- MAX 56.36
- Support Level
- NTLA $8.93
- MAX $9.79
- Resistance Level
- NTLA $9.79
- MAX $10.60
- Average True Range (ATR)
- NTLA 0.58
- MAX 0.31
- MACD
- NTLA -0.15
- MAX -0.03
- Stochastic Oscillator
- NTLA 1.35
- MAX 41.98
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.